Harlequin-Type Ichthyosis Fetalis

Harlequin ichthyosis is a very rare, severe genetic skin condition present at birth. Affected babies are born with very thick, hard skin that forms large diamond-shaped plates separated by deep cracks (fissures). The tight plates can pull the eyelids outward (ectropion), turn the lips outward (eclabium), flatten the ears and nose, limit movement of arms and legs, and make breathing and feeding difficult. The condition is life-threatening in the newborn period and needs intensive care. It happens because a specific skin protein, made by the ABCA12 gene, does not work well, so the outer skin barrier cannot form normally. Without a proper barrier, water is lost, germs enter more easily, and the skin cannot stretch and protect as it should. MedlinePlus+1

Harlequin ichthyosis is a very rare, severe, inherited skin disease. Babies are born with very thick, hard plates of skin that form large diamond-shaped scales separated by deep red cracks. The tight skin can pull the eyelids outwards (ectropion), pull the lips back (eclabium), make breathing and feeding hard, and increase the risk of infection? and dehydration?. The condition is caused by harmful changes (mutations) in a single gene called ABCA12. This gene helps skin cells move oily lipids to the skin surface to build a strong “waterproof” barrier. When ABCA12 does not work, the barrier is weak. Moisture is lost, germs can enter more easily, and the skin overgrows in a disorganized way. HI is passed on in an autosomal recessive pattern, meaning a child gets one nonworking copy of ABCA12 from each parent. Early intensive newborn care and careful skin treatment can improve survival compared with the past. Cell+4NCBI+4Orpha+4

ABCA12 is a “lipid transporter” in the outer skin cells. It moves fats that are needed to build the waterproof outer layer of the skin. When both copies of the ABCA12 gene carry harmful variants (autosomal recessive inheritance), the skin’s fat layers and tiny “lamellar bodies” do not form correctly, so the barrier fails. This explains the thick plates at birth and the high risks of dehydration?, infection?, and problems with temperature control. JCI+1

Outcomes have improved compared with the past because of modern newborn intensive care, infection? control, careful skin care, and (in selected cases) oral retinoid medicines that help thin and shed the thick skin. Survivors often grow into childhood and adulthood with ongoing, but manageable, ichthyosis. PMC+1

Other names

You may also see harlequin ichthyosis called “harlequin fetus,” “harlequin baby,” or “autosomal recessive congenital? ichthyosis—harlequin type”. In classification systems of inherited, non-syndromic ichthyoses, it is the most severe form of the ARCI group. (Today, many clinicians avoid using “fetus/baby” labels in favor of “harlequin ichthyosis.”) Orpha+1

Types

Doctors usually place harlequin ichthyosis within the ARCI spectrum alongside lamellar ichthyosis and congenital? ichthyosiform erythroderma. Harlequin type is the most severe at birth. Over time, with treatment and survival, the skin appearance can “evolve” into a chronic? ichthyosis pattern. In genetics, different ABCA12 variant patterns can roughly group cases into loss-of-function (very little or no protein) versus missense (protein present but faulty); complete loss tends to cause the most severe neonatal picture. MDPI+1

Some teams also speak about prenatal/ultrasound?-detectable HI (features visible before birth), classic neonatal HI (the plate-like armor at delivery), and survivor phenotype (long-term ichthyosis with ongoing care). These are practical, descriptive “types” based on timing and severity rather than completely separate diseases. PubMed

Causes

Harlequin ichthyosis has one core cause—biallelic pathogenic variants in ABCA12—but there are many ways that gene can be altered. Below are 20 plain-language “cause pathways,” all describing how ABCA12 can be damaged or disrupted so the skin barrier fails:

1. Stop-gain (nonsense) variants that prematurely end the protein, leaving it nonfunctional. JCI

2. Frameshift variants that scramble the protein code so it cannot work. JCI

3. Canonical splice-site variants that make the cell cut and paste the gene’s message incorrectly, producing a faulty protein. MDPI

4. Missense variants in critical domains (like the ATP-binding cassettes) that leave a full-length but weak transporter. Severe missense in key spots can behave like loss-of-function. ScienceDirect

5. Large deletions removing one or more exons, so big sections of the gene are missing. MDPI

6. Large duplications that disrupt normal reading of the gene and protein folding. MDPI

7. Compound heterozygosity (two different harmful variants, one from each parent) that together knock out function. MDPI

8. Two truncating variants (both copies) causing near-complete absence of ABCA12 and a classic severe neonatal presentation. MedlinePlus

9. Promoter/regulatory variants that reduce how much ABCA12 is made. (Less common, but reported in ARCI genes.) MDPI

10. Microdeletions at the ABCA12 locus that remove the gene’s key segments. MDPI

11. De novo ABCA12 variant plus inherited variant (rare) leading to biallelic damage. MDPI

12. Founder variants in certain populations increasing the chance carriers meet. MDPI

13. Consanguinity (parents related by blood), raising the chance both carry the same ABCA12 variant. (This is a risk context that unmasks the genetic cause.) MDPI

14. Severe missense variants in transmembrane domains that block lipid transport. JCI

15. Variants damaging trafficking signals so the protein cannot reach the right spot in the cell. JCI

16. Splice-region “leaky” variants that still make some normal protein, sometimes linked with survival and milder long-term skin. MDPI

17. ABCA12 exon skipping events documented on RNA studies, reducing full protein output. MDPI

18. Multi-exon rearrangements producing unstable messenger RNA. MDPI

19. Pathogenic intronic variants creating hidden splice sites and defective protein. MDPI

20. Complete biallelic null state (no functional protein at all)—the most severe cause pattern. MedlinePlus

Bottom line: different ABCA12 variant types all lead to the same root problem—lipids are not transported into the outer skin layers, so the waterproof barrier cannot form. JCI

Symptoms and signs

1) Thick, plate-like skin with deep cracks at birth. These diamond-shaped plates are the hallmark. They restrict movement and split with motion. MedlinePlus

2) Ectropion (eyelids pulled outward). The plates around the eyes pull the lids away, drying the eyes and risking injury. MedlinePlus

3) Eclabium (lips everted). Tight plates around the mouth turn the lips out, making feeding and sealing the mouth difficult. MedlinePlus

4) Flattened or small-appearing ears and nose. The plates mold the facial features. Ear canals can be narrowed by scale. MedlinePlus

5) Restricted limb movement and contractures. The skin acts like a rigid shell, limiting joint motion and sometimes bending fingers or toes. MedlinePlus

6) Respiratory distress. Tight chest skin and fissures can impair chest expansion, and fissures can hurt with breathing. PMC

7) Feeding difficulty and poor weight gain. Eclabium, pain? from fissures, and high energy needs make feeding hard. PMC

8) Dehydration? and electrolyte problems. The broken barrier loses water and salt, causing hypernatremia and instability. MedlinePlus

9) Temperature instability. The defective barrier and reduced sweating make it hard to keep normal body temperature. PMC

10) High risk of skin and systemic? infections. Cracked skin invites bacteria, and hospital care must minimize infection? risk. MedlinePlus

11) Pain? from fissures. Deep splits are painful and can bleed. Care teams use dressings and pain? control. PMC

12) Eye irritation and exposure keratopathy. Ectropion dries the cornea unless protected with lubricant and shielding. PMC

13) Hearing problems from blocked canals. Scale can fill the ear canals; careful cleaning improves hearing. PMC

14) Nail and hair changes. Nails may be dystrophic; hair can be sparse because scale blocks follicles. PMC

15) Prematurity and low birth weight are more common. Many infants are born early, adding to breathing and feeding risks. MedlinePlus

Diagnostic tests

A) Physical examination (what clinicians see and measure)

1) Newborn skin exam. Doctors look for the typical plate-like armor with deep fissures, plus ectropion and eclabium. This bedside exam strongly suggests the diagnosis? at birth. MedlinePlus

2) Vital signs and fluid status check. Frequent checks of temperature, heart rate, breathing, weight, and urine output help detect dehydration?, infection?, and temperature instability early. PMC

3) Eye surface exam. The team inspects the cornea and eyelids for drying and injury because ectropion exposes the eyes. PMC

4) Mouth and feeding assessment. Eclabium and tight perioral skin are noted; feeding ability and risk of aspiration are checked. PMC

5) Musculoskeletal exam. Range of motion, digit flexion/contractures, and chest wall movement are assessed because the rigid skin limits movement. PMC

B) Manual/bedside tests (simple practical checks without big machines)

6) Pain? scoring and wound assessment. Regular gentle scoring of pain? and inspection of fissures guide dressings and analgesia. PMC

7) Hydration checks (capillary refill/skin turgor adapted for thick skin). Even with thick plates, clinicians use modified signs plus inputs/outputs to judge dehydration?. PMC

8) Bedside glucose monitoring. Sick newborns can have low or high sugars; quick checks guide feeding and IV support. PMC

9) Pulse oximetry. A small light-clip on a hand or foot monitors oxygen saturation continuously when breathing is a concern. PMC

10) Newborn hearing screen (OAE/ABR). Scale may block ear canals; otoacoustic emissions or auditory brainstem response screens identify hearing issues early. (ABR is an electrodiagnostic-type test done at the bedside.) PMC

C) Laboratory and pathological tests (objective tests on samples)

11) Serum electrolytes and blood gases. Sodium and other salts can swing with water loss; blood gases show breathing and acid-base status. MedlinePlus

12) Complete blood count and infection? markers. White cells, C-reactive protein, and cultures are checked if infection? is suspected. PMC

13) Genetic testing for ABCA12. The most important confirmatory test: sequencing and copy-number analysis of ABCA12 to find two pathogenic variants. This confirms the diagnosis? and helps with family counseling. MDPI

14) Targeted parental testing. Testing both parents for the baby’s variants confirms carrier status and guides recurrence risk (25% for each pregnancy). MDPI

15) Skin biopsy? (if needed). Microscopy can show very thick outer skin (orthokeratotic hyperkeratosis) and, on electron microscopy, absent lamellar bodies and lipid bilayers, which fits harlequin ichthyosis. In fragile newborns, many centers now prefer genetic testing over biopsy?. NCBI

16) Metabolic panel (kidney/liver) and nutrition labs. These track organ function and nutrition during intensive care and retinoid use if prescribed. PMC

D) Electrodiagnostic tests (recording body signals)

17) Auditory brainstem response (ABR). This measures the brain’s response to sound and helps confirm hearing status when canals are obstructed by scale. PMC

18) Electrocardiogram (ECG). Significant electrolyte disturbances (like high sodium or potassium shifts) and some medicines can affect the heart rhythm; ECGs monitor for safety in the NICU. PMC

E) Imaging tests (seeing features before or after birth)

19) Prenatal ultrasound? (2D and 3D). From the late second to third trimester, ultrasound? may show wide-open mouth, everted lips, flat nose, ectropion, clenched hands/clubfeet, growth restriction, and even “echogenic” (cloudy) amniotic fluid from shedding skin. 3D ultrasound improves facial detail and can support prenatal counseling. Obstetrics & Gynecology+2PubMed+2

20) Prenatal MRI or targeted postnatal imaging. Fetal MRI can add soft-tissue detail when ultrasound? is limited. After birth, chest X-rays may be used to evaluate breathing issues; imaging is tailored to the infant’s clinical needs.

Here’s a comprehensive, plain-English guide to harlequin-type ichthyosis (harlequin ichthyosis, HI) with evidence-based references in every paragraph. I’ve kept the language simple while grounding each section in peer-reviewed or official sources, including FDA labels for medicines where relevant.

Non-pharmacological treatments (therapies & others)

1. Warm, humidified incubator care (newborn period). Purpose: reduce water loss, keep body temperature stable, soften thick plates, and support breathing. Mechanism: humidity lowers transepidermal water loss and softens hyperkeratotic skin; warmth supports fragile thermoregulation. SAGE Journals

2. Generous bland emollients (e.g., petrolatum) many times daily. Purpose: keep skin moist, reduce cracking and pain?, support barrier function. Mechanism: occlusion and lipid replacement reduce evaporation and fill gaps in the faulty stratum corneum. Medscape

3. Sterile saline soaks/compresses before emollients. Purpose: soften and lift crusting, allow safer removal of debris, and prepare skin for moisturizers. Mechanism: gentle hydration loosens hyperkeratotic plates to reduce fissuring when skin moves. Medscape

4. Careful debridement of thick plates by trained staff. Purpose: gradually reduce constricting plaques that can restrict movement or breathing. Mechanism: mechanical reduction of plates decreases tension and improves skin flexibility; must be sterile and gentle to avoid bleeding/infection?. PMC

5. Eye protection & lubrication. Purpose: protect exposed eyes (ectropion) from drying and ulceration. Mechanism: frequent ocular lubricants and ophthalmology review preserve the cornea and prevent infection?. PMC+1

6. Mouth and airway care. Purpose: reduce feeding and breathing problems from tight facial skin. Mechanism: careful mouth care, positioning, and ENT support maintain airway patency and improve feeding safety. Medscape

7. Feeding support (breast/bottle with occupational therapy input). Purpose: maintain growth and prevent failure to thrive when feeding is difficult. Mechanism: tailored techniques, NG feeding if needed, and calorie-dense nutrition overcome increased metabolic demands from skin repair. Medscape

8. Temperature control & hydration monitoring. Purpose: prevent overheating or cooling and dehydration? due to barrier failure. Mechanism: frequent vitals and fluid balance checks compensate for excessive water loss through the skin. Europe PMC

9. Infection prevention bundle. Purpose: lower sepsis risk. Mechanism: sterile handling, early treatment of fissures, and skin/eye care reduce bacterial entry through cracks. PMC

10. Pain management plan. Purpose: reduce pain from fissures and procedures. Mechanism: stepwise analgesia and gentle handling limit stress and allow better feeding and sleep. PMC

11. Physical and occupational therapy (later infancy/childhood). Purpose: improve range of motion, prevent contractures, and support function. Mechanism: stretching, splinting if needed, and activity plans counter stiffness from scaly plaques. PMC

12. Sun and heat protection. Purpose: avoid overheating and sunburn in vulnerable skin. Mechanism: shade, clothing, and schedule planning reduce UV/heat stress on a weak barrier. Medscape

13. Gentle bathing routine (no harsh soaps). Purpose: cleanse without stripping lipids. Mechanism: tepid water and mild cleansers reduce irritation; immediate emollient “soak and seal” locks water in. Medscape

14. Nail and fissure care. Purpose: prevent secondary infection from scratching and open cracks. Mechanism: short nails, emollients in fissures, and wound care decrease bacterial entry. PMC

15. Regular dermatology follow-up & care plans. Purpose: adapt treatments over time and manage complications. Mechanism: scheduled reviews detect infections, ear canal scaling, or eye problems early. Cell

16. Genetic counseling for the family. Purpose: understand inheritance, carrier testing, and options for future pregnancies. Mechanism: explain ABCA12 recessive transmission; discuss prenatal testing and preimplantation genetic testing (PGT). NCBI+1

17. Prenatal imaging and molecular testing in future pregnancies. Purpose: early diagnosis to plan perinatal care. Mechanism: targeted ultrasound and ABCA12 testing can detect or confirm HI prenatally in some cases. PMC+1

18. Psychosocial support for parents/caregivers. Purpose: reduce distress and improve coping with long-term care. Mechanism: counseling, support groups, and social services address the emotional and practical load. Europe PMC

19. School and community plans. Purpose: enable safe participation and skin-friendly routines. Mechanism: temperature control, hydration breaks, and gentle cleansers at school reduce flares. Europe PMC

20. Transition planning to adult care. Purpose: continuous, coordinated care across life stages. Mechanism: structured handover maintains access to dermatology, ophthalmology, dental, and mental-health services. Europe PMC

Drug treatments

Important: No medicine is formally FDA-approved for HI specifically; several are used off-label by specialists. Dosing in newborns/children must be individualized by experienced teams. I cite FDA labels for safety/pharmacology, plus clinical literature for HI use.

1. Acitretin (oral retinoid). Class: systemic retinoid. Typical use: short neonatal courses (specialist-directed) or intermittent use later. Purpose: thin hyperkeratosis and improve plate shedding. Mechanism: normalizes epidermal differentiation via retinoic-acid receptors. Key safety: strict pregnancy contraindication for years after therapy; monitor liver, lipids. (FDA Soriatane® label). JAMA Network+3FDA Access Data+3FDA Access Data+3

2. Isotretinoin (oral retinoid). Class: systemic retinoid. Purpose: similar to acitretin; some centers prefer isotretinoin in neonates. Mechanism: reduces pathologic keratinization. Safety: boxed teratogenicity warnings; iPLEDGE in acne; specialist oversight essential. (FDA Accutane®/Absorica® labeling). FDA Access Data+1

3. Tazarotene (topical retinoid, later childhood/adults to spots). Class: topical RAR agonist. Purpose: soften localized plaques. Mechanism: retinoid-mediated normalization of keratinocyte differentiation. Safety: avoid in pregnancy; may irritate. (FDA Tazarotene labels). FDA Access Data+1

4. Urea creams/lotions (topical keratolytic). Class: humectant/keratolytic. Purpose: soften scaling and reduce fissuring. Mechanism: draws water and breaks hydrogen bonds in keratin to loosen scale; use gentle strengths, avoid overuse in infants. (FDA/DailyMed entries note status and precautions). DailyMed

5. Salicylic acid (topical keratolytic, cautious use). Class: keratolytic. Purpose: reduce thick localized plaques in older children/adults only. Mechanism: breaks intercellular bonds in stratum corneum; risk of systemic salicylate toxicity in infants/large areas—use sparingly, if at all. (FDA SPL data). FDA Access Data+1

6. Antibiotics (systemic when infection is proven/suspected). Class: varies (e.g., beta-lactams). Purpose: treat skin/soft-tissue infections and sepsis risk from fissures. Mechanism: kill or inhibit bacteria; antibiotic choice guided by cultures and neonatology protocols. (General management reviews). PMC

7. Topical antibiotics for focal secondary infection. Class: e.g., mupirocin. Purpose: short courses to treat localized impetigo-like areas. Mechanism: reduce bacterial load at fissures; avoid routine prolonged use to limit resistance. (Management reviews). PMC

8. Antifungals (when Candida or dermatophytes complicate care). Class: topical/systemic per culture. Purpose: treat superinfection in macerated folds. Mechanism: inhibit fungal cell membranes. (Management reviews). PMC

9. Ocular lubricants and ophthalmic antibiotics. Class: artificial tears/ointments; topical antibiotics if keratitis. Purpose: prevent corneal drying and infection with ectropion. Mechanism: tear film replacement; antimicrobial coverage when indicated. (Ophthalmic HI review). PMC

10. Analgesics (acetaminophen/others as directed). Class: antipyretic/analgesic. Purpose: relieve pain from fissures and procedures. Mechanism: central COX effect; dosing by weight and age. (Neonatal care overviews). Europe PMC

11. Antihistamines (sedating at night if pruritus disrupts sleep in older children). Class: H1 antagonists. Purpose: itch relief and sleep support. Mechanism: block histamine receptors; use age-appropriate dosing. (General ichthyosis care). Europe PMC

12. Topical calcineurin inhibitors (for inflamed folds/eyelids in older children). Class: tacrolimus/pimecrolimus. Purpose: reduce inflammation without steroid thinning. Mechanism: blocks T-cell activation. (General pediatric derm use). Europe PMC

13. Short, cautious topical corticosteroids (select inflamed areas). Class: anti-inflammatory. Purpose: calm dermatitis around fissures; avoid long-term use. Mechanism: suppress cytokines. (General practice notes). Europe PMC

14. Barrier repair creams with ceramides (adjunct). Class: emollients. Purpose: support missing lipids in stratum corneum. Mechanism: replace ceramides to reduce water loss. (Barrier literature). BioMed Central

15. Nasal saline and humidification. Class: supportive. Purpose: help breathing comfort if nasal crusting occurs. Mechanism: moisturizes mucosa. (Care overviews). Europe PMC

16. Vitamin D supplementation if deficient (per labs). Class: nutrient. Purpose: correct deficiency that may occur with limited sun exposure and barrier loss. Mechanism: restores systemic levels; not a primary HI treatment. (General guidance). Europe PMC

17. Zinc supplementation if deficient (per labs). Class: nutrient. Purpose: support wound healing if low. Mechanism: cofactor for tissue repair; not specific to HI. (General pediatric nutrition). Europe PMC

18. Topical antiseptics (short courses, peri-procedural). Class: chlorhexidine, etc. Purpose: lower skin bacterial load before debridement/dressings. Mechanism: broad antimicrobial action; avoid irritation. (Management reports). PMC

19. Lactic acid/ammonium lactate (older children/adults). Class: alpha-hydroxy keratolytic. Purpose: soften scaling; may sting on fissures. Mechanism: disrupts corneocyte cohesion and adds humectancy. (General ichthyosis care). Europe PMC

20. Retinoid stewardship & monitoring protocols. Class: safety process. Purpose: minimize retinoid adverse effects; ensure pregnancy prevention and lab monitoring. Mechanism: standardized labs (LFTs/lipids), contraception counseling (where applicable), shortest effective courses. (FDA acitretin/isotretinoin labeling). FDA Access Data+1

Dietary molecular supplements

1. Omega-3 fatty acids (fish oil). May modestly reduce inflammation and support barrier lipids; aim for standard pediatric dosing if used. Mechanism: alters eicosanoids; anti-inflammatory profile. Evidence in HI is inferential from barrier disorders, not definitive. Europe PMC

2. Ceramide-rich oral nutraceuticals (emerging/limited data). Goal: support lipid barrier from within; mechanism: provide sphingolipid precursors. Evidence remains limited; topical ceramides are primary. BioMed Central

3. Vitamin D (correct deficiency only). Mechanism: immunomodulation and keratinocyte function; dose per labs to normal range. Over-supplementation risks hypercalcemia. Europe PMC

4. Zinc (correct deficiency only). Supports wound healing/immune function; excess causes copper deficiency. Europe PMC

5. Biotin (only if deficiency suspected). Some hair/skin benefits in deficiency states; routine use lacks evidence in HI. Europe PMC

6. Probiotics (general gut/immune support; evidence uncertain in HI). Mechanism: microbiome modulation may influence skin inflammation; choose pediatric-tested strains. Europe PMC

7. Evening primrose oil (gamma-linolenic acid; limited evidence). Potential anti-inflammatory effect via prostaglandins; monitor for GI upset. Europe PMC

8. Multivitamin to meet RDAs (not megadoses). Compensates for increased demands; avoid excess vitamin A with retinoids. Europe PMC

9. Oral rehydration solutions (as diet adjunct when ill). Helps maintain fluid balance during fevers or infections. Europe PMC

10. Protein-adequate diet supplements. Supports growth and skin repair; dietician-guided. Europe PMC

Immunity-booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity-booster,” regenerative, or stem-cell drugs for harlequin ichthyosis. The FDA warns that many stem-cell and exosome products marketed directly to consumers are unapproved and risky (reports include infections, blindness, and tumors). Only certain umbilical-cord blood products are FDA-approved, and those are for blood disorders, not skin diseases like HI. If you are offered stem-cell or regenerative injections or creams for HI outside a regulated clinical trial, it is not an approved therapy. U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3

Surgeries / procedures

1. Release of constriction bands (digits/limbs). Why: tight plates can constrict blood flow to fingers or toes. Procedure: careful surgical release or bedside lysis to restore circulation. PMC

2. Ectropion repair (later childhood). Why: persistent eyelid eversion risks corneal injury. Procedure: oculoplastic techniques to improve eyelid position. PMC

3. Eclabium reduction (selected cases). Why: severe lip eversion can impair feeding/speech. Procedure: surgical soft-tissue balancing once skin is healthier. PMC

4. Debridement under anesthesia (exceptional cases). Why: remove very thick, immobile plates that threaten breathing or perfusion. Procedure: controlled removal with sterile technique and post-op emollients. PMC

5. Corneal procedures for ulcers (when conservative care fails). Why: protect vision. Procedure: ophthalmology-led options (bandage lens, tarsorrhaphy) depending on severity. PMC

Prevention strategies

1. Genetic counseling for both parents to understand autosomal recessive inheritance and carrier risks. NCBI

2. Carrier testing for family members where appropriate. NCBI

3. Prenatal molecular testing in future pregnancies when familial ABCA12 variants are known. PMC

4. Targeted late-pregnancy ultrasound to look for suggestive signs and plan delivery at a center with NICU/dermatology. BioMed Central

5. Early delivery planning with a multidisciplinary team (neonatology, dermatology, ophthalmology, ENT). Europe PMC

6. NICU readiness for humidified incubator, emollients, and eye care at birth. SAGE Journals

7. Strict infection control practices in hospital and at home. PMC

8. Education on daily skin routines (soak-and-seal, gentle cleansers, prompt fissure care). Medscape

9. Sun/heat avoidance plans to prevent overheating and flares. Medscape

10. Regular follow-up schedules to catch complications early and adjust care. Cell

When to see doctors urgently

Seek urgent medical care for fever, spreading redness, pus or foul odor, breathing difficulty, poor feeding or dehydration (few wet diapers, lethargy), new eye pain/redness/vision changes, or sudden swelling or dusky color of fingers/toes (possible constriction). Early treatment can prevent sepsis, eye damage, or tissue loss. Keep regular dermatology and pediatric follow-ups even when things look stable. PMC+1

What to eat and what to avoid

What to include: balanced calories with enough protein for skin repair; adequate fluids; vitamin D and zinc if deficient (doctor-guided); and energy-dense foods if growth is slow. What to avoid: extreme vitamin-A supplements (dangerous with retinoids), unnecessary herbal/stem-cell “boosters,” harsh spices/acidic foods that sting perioral fissures, and dehydration during hot weather. Work with a pediatric dietitian for individualized plans. Europe PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 06, 2025.